In:
Neuroendocrinology, S. Karger AG, Vol. 79, No. 3 ( 2004), p. 142-148
Abstract:
The role of somatostatin (SS) receptor subtype 1 (SSTR 〈 sub 〉 1 〈 /sub 〉 ) in mediating the inhibitory effect of SS on growth hormone (GH) secreting pituitary tumors has been recently demonstrated. In the present study, we evaluated the effect of the selective SSTR 〈 sub 〉 1 〈 /sub 〉 agonist BIM-23745 on in vitro GH secretion in GH-secreting pituitary tumor cells, deriving from patients resistant or partially responsive to octreotide long-acting release (octreotide-LAR) or lanreotide therapy in vivo and expressing SSTR 〈 sub 〉 1 〈 /sub 〉 mRNA. In addition, the inhibiting effect of BIM-23745 on the GH secretion was compared with that of octreotide. Our data demonstrate that (1) SSTR 〈 sub 〉 1 〈 /sub 〉 receptor was present in 56.25% (9/16) of the GH-secreting adenomas examined; (2) in all GH-secreting pituitary tumors that expressed SSTR 〈 sub 〉 1 〈 /sub 〉 , BIM-23745 significantly inhibited GH secretion in vitro, and (3) when SSTR 〈 sub 〉 1 〈 /sub 〉 subtype was present in tumors from patients resistant to octreotide-LAR or lanreotide therapy, BIM-23745 was able to inhibit the in vitro GH secretion. In conclusion, the results of the current study suggest that SS analogs selective for the SSTR 〈 sub 〉 1 〈 /sub 〉 may represent a further useful approach for the treatment of acromegaly in patients resistant or partially responsive to octreotide-LAR or lanreotide treatment in vivo.
Type of Medium:
Online Resource
ISSN:
0028-3835
,
1423-0194
Language:
English
Publisher:
S. Karger AG
Publication Date:
2004
detail.hit.zdb_id:
1483028-0
Permalink